An International, Multicenter, Randomized, Double-Blind, Parallel-Group Phase 2 Study Evaluating the Safety and Efficacy of Diacerein 1% Ointment Topical Formulation in Subjects With Epidermolysis Bullosa Simplex (EBS)
Phase of Trial: Phase II
Latest Information Update: 27 Oct 2017
At a glance
- Drugs Diacerein (Primary)
- Indications Epidermolysis bullosa
- Focus Therapeutic Use
- Acronyms DELIVERS
- Sponsors Castle Creek Pharmaceuticals
- 27 Oct 2017 According to a Castle Creek Pharmaceuticals media release, the first was enrolled in this study in June 2017.
- 01 Jun 2017 Status changed from not yet recruiting to recruiting.
- 19 May 2017 New trial record